Repligen to acquire BioLife Solutions for about $1.5 billion

Repligen Corporation and BioLife Solutions, Inc. announced on July 22, 2026 that they have signed a definitive merger agreement under which Repligen will acquire BioLife. The transaction carries a total enterprise value of approximately $1.5 billion, made up of 64% Repligen common stock and 36% cash.¹

Under the terms, each share of BioLife common stock will convert into the right to receive 0.1442 shares of Repligen common stock plus $11.25 in cash without interest¹, which the companies said represents an implied premium of 24% to BioLife's 90-day volume-weighted average price for the period ended July 21, 2026.¹

Alongside the deal, both companies disclosed preliminary second-quarter 2026 figures. Repligen expects revenue growth of about 12% as reported and 13% on an organic basis compared with the same period in 2025.¹ BioLife expects preliminary second-quarter revenue of $28.5 million, up 21% from $23.4 million in the second quarter of 2025.¹ Both companies noted these figures are unaudited. The preliminary results are subject to change pending completion of each company's quarter-end financial close process.¹

The transaction is expected to close in the fourth quarter of 2026, subject to customary regulatory approvals, approval by BioLife stockholders, and other customary closing conditions in the merger agreement.¹ The 8-K also spells out an outside date and termination provisions: either party may terminate the agreement if the mergers have not closed by 5:00 p.m. New York time on January 31, 2027, subject to possible extensions tied to antitrust review or SEC registration timing.¹ Under certain specified circumstances involving a competing proposal, BioLife may be required to pay Repligen a termination fee of $59,000,000.¹

Directors of both companies backed the deal, as the directors of each company unanimously approved the transaction.¹ Advisors on the deal include Perella Weinberg and Goldman Sachs for Repligen and Centerview Partners for BioLife, according to the filing.